Skip to main content

Table 2 Adjusted odds ratios for non-localised (regional and distant) stage of breast cancers at diagnosis by country of birth; New South Wales 2003–2016a

From: Female breast cancer in New South Wales, Australia, by country of birth: implications for health-service delivery

Predictor

Number (%) with non-localised stage (total 21,630, out of 46,779)

aOR non-localised (95% confidence limits)

Country of birth

Australia (ref.) n = 13,773 (45.4)

1.000

China (mainland) n = 484 (46.3)

0.967 (0.853,1.095)

Germany n = 212 (49.3)

1.249 (1.031,1.512)

Greece n = 251 (50.0)

1.301 (1.090,1.553)

Italy n = 374 (51.0)

1.328 (1.146,1.539)

Lebanon n = 326 (55.2)

1.400 (1.186,1.651)

New Zealand n = 476 (47.4)

1.038 (0.915,1.179)

Philippines n = 367 (47.8)

1.050 (0.908,1.213)

United Kingdom n = 1478 (44.8)

1.005 (0.935,1.081)

Vietnam n = 217 (45.0)

0.862 (0.717,1.036)

Other mainly English. Speaking n = 393 (46.9)

1.079 (0.939,1.239)

Other mainly non-English speaking n = 3279 (48.6)

1.123 (1.064,1.184)

Age at diagnosis (years)

18 to 49 (ref.) n = 6348 (53.8)

1.000

50–59 n = 5631 (45.6)

0.714 (0.678,0.751)

60–69 n = 4753 (40.0)

0.564 (0.535,0.594)

70+ n = 4898 (45.7)

0.699 (0.663,0.738)

SEIFA SES Disadvantage

1 (most) (ref.) n = 4008 (48.0)

1.000

2 n = 4057 (47.2)

0.960 (0.904,1.021)

3 n = 4048 (45.8)

0.899 (0.847,0.956)

4 n = 4517 (46.3)

0.916 (0.863,0.973)

5 (least) n = 5000 (44.5)

0.848 (0.801,0.899)

Year of diagnosis

Continuous (2003–16) n = 21,630

0.995 (0.991,1.000)

Comorbidity Index (Charlson)

0 (ref.) n = 20,979 (46.1)

1.000

> 0 n = 651 (50.3)

1.238 (1.106,1.385)

  1. aFemale cases only – 95.6% with treatment details; Multivariate logistic regression adjusted for age, SES, diagnostic year and comorbidity; Excludes multiple primary cancers and local health districts bordering other states/territories (see text)
  2. aOR adjusted odds ratio, SEIFA SES Socio-Economic Indexes for Areas, ref reference